[Clinical study on tangweikang capsule in treating diabetic nephropathy].
To observe the effect of Tangweikang capsule (TWKC) in treating diabetic nephropathy (DN). The 119 patients enrolled were divided into 2 groups, 78 patients in the TWKC group treated with TWKC and 41 patients in the control group treated with Captopril. The changes of symptom score, urinary microprotein series (urinary albumin excretion rate, Tamm-horsfall protein and beta 2-microglobulin), blood glucose, kidney function, blood lipid, angiotensin I (A I) and II (A II), atrial natriuretic polypeptide (ANP), thromboxane B2(TXB2), 6-keto-prostaglandin F1 alpha, endothelin 1 (ET-1) and collagen IV in patients after treatment were observed. The total effective rate in the TWKC group was 84.62%, which was superior to that in the control group (70.73%, P < 0.05). TWKC also showed better effects in improving clinical symptoms, lowering blood glucose, urinary microprotein series, blood lipid, A I, A II, ANP, ET-1 and collagen IV, ameliorating kidney function, and adjusting dynamic equilibrium of thromboxane-prostacyclin system, as compared with the control group (P < 0.05 or P < 0.01). TWKC could lower the levels of blood glucose and lipid, improve the glucose and lipid metabolism, regulate the microcirculation, ameliorate the degree of kidney damage, therefore, it showed a better effect in treating diabetic nephropathy.